COVID-19 Impact on Patients with Immune-Mediated Rheumatic Disease: A Comparative Study of Disease Activity and Psychological Well-Being Over Six Months

CLAUDIA DINIZ LOPES MARQUES, Marcelo Pinheiro, Jeniffer Lopes, Sandra Lucia Euzebio Ribeiro, Mary Vania Marinho Castro, Lilian David de Azevedo Valadares, Aline Ranzolin, Nicole Pamplona Bueno de Andrada, Rafaela Cavalheiro do Espirito Santo, Nafice Costa Araujo, Cintya Martins Vieira, Valeria Valim, Flavia Santos, Laurindo Ferreira da Rocha Junior, Adriana Maria Kakehasi, Ana Paula Monteiro Gomides Reis, Edgard Torres Neto, Gecilmara Pilegii, Gilda Aparecida Ferreira, Licia Mota, Odirlei Monticielo, Ricardo Machado Xavier
{"title":"COVID-19 Impact on Patients with Immune-Mediated Rheumatic Disease: A Comparative Study of Disease Activity and Psychological Well-Being Over Six Months","authors":"CLAUDIA DINIZ LOPES MARQUES, Marcelo Pinheiro, Jeniffer Lopes, Sandra Lucia Euzebio Ribeiro, Mary Vania Marinho Castro, Lilian David de Azevedo Valadares, Aline Ranzolin, Nicole Pamplona Bueno de Andrada, Rafaela Cavalheiro do Espirito Santo, Nafice Costa Araujo, Cintya Martins Vieira, Valeria Valim, Flavia Santos, Laurindo Ferreira da Rocha Junior, Adriana Maria Kakehasi, Ana Paula Monteiro Gomides Reis, Edgard Torres Neto, Gecilmara Pilegii, Gilda Aparecida Ferreira, Licia Mota, Odirlei Monticielo, Ricardo Machado Xavier","doi":"10.1101/2024.03.18.24304464","DOIUrl":null,"url":null,"abstract":"Objectives: To compare the impact of COVID-19 on clinical status and psychological condition in patients with immune-mediated rheumatic diseases (IMRD) infected by SARS-CoV-2 with IMRD controls not infected, during a 6-month follow-up.\nMethods: The ReumaCoV Brasil is a longitudinal study designed to follow-up IMRD patients for 6 months after COVID-19 (cases) compared with IMRD patients no COVID-19 (controls). Clinical data, disease activity measurements and current treatment regarding IMRD, and COVID-19 outcomes were evaluated in all patients. Disease activity was assessed through validated tools at inclusion and at 3 and 6 months post-COVID-19. The FACIT-F (Functional Assessment of Chronic Illness Therapy) and DASS 21 (Depression, Anxiety and Stress Scale - 21 Items) questionnaires were also applied at 6 months after COVID-19 in both groups before large-scale vaccination. The significance level was set as p<0.05, with a 95% confidence interval.\nResults: A total of 601 patients were evaluated, being 321 cases (IMRD COVID-19+) and 280 controls (IMRD COVID-19 -), predominantly female with similar median age. No significant differences were noted in demographic data between the groups, including comorbidities, disease duration, and IMRD. Disease activity assessment over a 6-month follow-up showed no significant difference between cases and controls. While mean activity scores did not differ significantly, some patients reported worsened disease activity post-COVID-19, particularly in rheumatoid arthritis (RA) (32.2%) and systemic lupus erythematosus (SLE) (23.3%). Post-COVID-19 worsening in RA patients correlated with medical global assessment (MGA) and CDAI scores, with a moderate to large effect size. Diabetes mellitus showed a positive association (OR=7.15), while TNF inhibitors showed a protective effect (OR=0.51). Comparing SLEDAI pre- and post-COVID-19, a minority showed increased scores, with few requiring treatment changes. Fatigue, depression, anxiety, and stress were significantly higher in cases compared to controls. Worsening disease activity post-COVID correlated with worsened FACIT-F and DASS-21 stress scale in RA patients. No significant associations were found between COVID-19 outcomes and post-COVID-19 disease activity or psychological assessments. Conclusions: Post-COVID-19 IMRD patients show significant psychological well-being deterioration despite similar disease activity scores. The variability in reports on IMRD flares and the potential trigger of SARS-CoV-2 for autoimmune manifestations underline the need for detailed clinical assessment and a comprehensive approach to managing them.","PeriodicalId":501212,"journal":{"name":"medRxiv - Rheumatology","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.03.18.24304464","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To compare the impact of COVID-19 on clinical status and psychological condition in patients with immune-mediated rheumatic diseases (IMRD) infected by SARS-CoV-2 with IMRD controls not infected, during a 6-month follow-up. Methods: The ReumaCoV Brasil is a longitudinal study designed to follow-up IMRD patients for 6 months after COVID-19 (cases) compared with IMRD patients no COVID-19 (controls). Clinical data, disease activity measurements and current treatment regarding IMRD, and COVID-19 outcomes were evaluated in all patients. Disease activity was assessed through validated tools at inclusion and at 3 and 6 months post-COVID-19. The FACIT-F (Functional Assessment of Chronic Illness Therapy) and DASS 21 (Depression, Anxiety and Stress Scale - 21 Items) questionnaires were also applied at 6 months after COVID-19 in both groups before large-scale vaccination. The significance level was set as p<0.05, with a 95% confidence interval. Results: A total of 601 patients were evaluated, being 321 cases (IMRD COVID-19+) and 280 controls (IMRD COVID-19 -), predominantly female with similar median age. No significant differences were noted in demographic data between the groups, including comorbidities, disease duration, and IMRD. Disease activity assessment over a 6-month follow-up showed no significant difference between cases and controls. While mean activity scores did not differ significantly, some patients reported worsened disease activity post-COVID-19, particularly in rheumatoid arthritis (RA) (32.2%) and systemic lupus erythematosus (SLE) (23.3%). Post-COVID-19 worsening in RA patients correlated with medical global assessment (MGA) and CDAI scores, with a moderate to large effect size. Diabetes mellitus showed a positive association (OR=7.15), while TNF inhibitors showed a protective effect (OR=0.51). Comparing SLEDAI pre- and post-COVID-19, a minority showed increased scores, with few requiring treatment changes. Fatigue, depression, anxiety, and stress were significantly higher in cases compared to controls. Worsening disease activity post-COVID correlated with worsened FACIT-F and DASS-21 stress scale in RA patients. No significant associations were found between COVID-19 outcomes and post-COVID-19 disease activity or psychological assessments. Conclusions: Post-COVID-19 IMRD patients show significant psychological well-being deterioration despite similar disease activity scores. The variability in reports on IMRD flares and the potential trigger of SARS-CoV-2 for autoimmune manifestations underline the need for detailed clinical assessment and a comprehensive approach to managing them.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19 对免疫性风湿病患者的影响:六个月内疾病活动和心理健康的比较研究
研究目的比较 COVID-19 对感染 SARS-CoV-2 的免疫介导风湿性疾病(IMRD)患者和未感染 SARS-CoV-2 的 IMRD 对照组患者在 6 个月随访期间的临床状态和心理状况的影响:ReumaCoV Brasil 是一项纵向研究,旨在对感染 COVID-19 后的 IMRD 患者(病例)与未感染 COVID-19 的 IMRD 患者(对照组)进行为期 6 个月的随访。研究评估了所有患者的临床数据、疾病活动性测量结果、目前对 IMRD 的治疗情况以及 COVID-19 的结果。在纳入COVID-19时以及COVID-19后3个月和6个月,疾病活动性通过有效工具进行评估。在大规模疫苗接种前,两组患者在接种 COVID-19 后 6 个月时还使用了 FACIT-F(慢性疾病治疗功能评估)和 DASS 21(抑郁、焦虑和压力量表 - 21 项)问卷。显著性水平定为 p<0.05,置信区间为 95%:共对 601 名患者进行了评估,其中病例 321 例(IMRD COVID-19 +),对照组 280 例(IMRD COVID-19 -),主要为女性,中位年龄相似。两组的人口统计学数据(包括合并症、病程和 IMRD)无明显差异。随访 6 个月的疾病活动评估显示,病例与对照组之间没有明显差异。虽然平均活动度评分没有明显差异,但一些患者报告称,COVID-19 后疾病活动度恶化,尤其是类风湿性关节炎(RA)(32.2%)和系统性红斑狼疮(SLE)(23.3%)。类风湿性关节炎(RA)患者COVID-19后的病情恶化与医学总体评估(MGA)和CDAI评分相关,具有中等至较大的效应规模。糖尿病与此呈正相关(OR=7.15),而 TNF 抑制剂具有保护作用(OR=0.51)。比较SLEDAI在COVID-19之前和之后的情况,少数人的得分有所增加,但很少有人需要改变治疗方案。与对照组相比,病例的疲劳、抑郁、焦虑和压力明显增加。COVID后疾病活动的恶化与RA患者FACIT-F和DASS-21压力量表的恶化相关。在COVID-19结果与COVID-19后疾病活动或心理评估之间没有发现明显的关联。结论尽管疾病活动评分相似,但COVID-19后IMRD患者的心理健康状况明显恶化。有关 IMRD 复发的报告存在差异,SARS-CoV-2 有可能诱发自身免疫表现,这突出表明有必要进行详细的临床评估并采取综合方法来管理这些患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Mosaic loss of chromosome Y characterizes late-onset rheumatoid arthritis and contrasting associations of polygenic risk score based on age at onset. Use of Metagenomic Microbial Plasma Cell-Free DNA Next-Generation Sequencing Assay in Outpatient Rheumatology Practice Proteomic profiling of the large vessel vasculitis spectrum identifies shared signatures of innate immune activation and stromal remodelling Pre-trained convolutional neural network with transfer learning by artificial illustrated images classify power Doppler ultrasound images of rheumatoid arthritis joints Associations between exposure to OPEs and rheumatoid arthritis risk among adults in NHANES, 2011-2018
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1